HMGB1 and status epilepticus: In acute stage of status epilepticus, intravenous therapy with neutralizing anti-HMGB1 monoclonal antibody exhibited neuroprotective effect on neuronal death, inhibition of HMGB1 release, blood brain barrier (BBB) protection and anti-inflammatory actions [34].